Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rohto Pharmaceutical Co ( (JP:4527) ) has shared an update.
Rohto Pharmaceutical has approved a share repurchase program of up to 1.5 million shares, equivalent to 0.66% of its outstanding stock excluding treasury shares, with a maximum outlay of ¥3 billion. The buyback, to be executed via market purchases on the Tokyo Stock Exchange between March 27 and December 31, 2026, is aimed at improving capital efficiency and giving management greater flexibility in executing capital policies, which may support shareholder returns and signal confidence in the company’s valuation.
As of March 26, 2026, Rohto holds 10,213,970 treasury shares out of 236,178,310 issued shares, leaving 225,964,340 shares outstanding excluding treasury stock. The additional repurchase capacity, though modest in size, further enhances the company’s ability to manage its balance sheet and may have a marginally positive impact on earnings per share and market perception if fully executed within the stated period.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2876.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a Japan-based healthcare company listed on the TSE Prime that develops and sells over-the-counter medicines, skincare, eye-care and other consumer health products. The company operates globally with a focus on improving profitability and capital efficiency while maintaining a stable shareholder base in the competitive pharmaceutical and consumer health markets.
Average Trading Volume: 773,144
Technical Sentiment Signal: Sell
Current Market Cap: Yen552.7B
Learn more about 4527 stock on TipRanks’ Stock Analysis page.